Federal Register / Vol. 66, No. 14 / Monday, January 22, 2001 / Notices 6637

Subject city, state Effective

date

East Meadow, NY

Appalachian Medical Supply .... 01/18/2001

Asheville, NC

Burnside Pharmacy .................. 01/18/2001

Burnside, KY

Genesee Hearing Svcs, LLP .... 01/18/2001

Buffalo, NY

Home Infusion Mgmt. Svc ........ 01/18/2001

Congers, NY

Medical Repair Center, Inc ....... 01/18/2001

La Mesa, CA

Willowbrook Medical Treatment 01/18/2001

Wayne, NJ

Default on Heal Loan

Ardalan, Mehrmaz .................... 01/18/2001

West Hills, CA

Booher-Fulton, Janette L .......... 01/18/2001

S. San Francisco, CA

Bunce, Christine T .................... 01/18/2001

Oakland, CA

Caldwell, Larry Von .................. 01/18/2001

Gretna, LA

Dominics, Beth Anne ................ 01/18/2001

Los Angeles, CA

Dowell, Alfonzo N Jr ................. 01/18/2001

Oklahoma City, OK

Farrell, Robert J ........................ 12/13/2000

San Diego, CA

Funcia, Ana T ........................... 01/18/2001

Miami, FL

Gieschen, John M .................... 01/18/2001

Santa Cruz, CA

Gillies, Douglas K ..................... 01/18/2001

Roswell, NM

Grant, Terry E ........................... 01/18/2001

Freeport, NY

Imani, Ibn A .............................. 11/21/2000

Tallahassee, Fl

Jakubczak, Arthur F ................. 01/18/2001

Perth Amboy, NJ

Jefferson, Michael Kenneth ...... 01/18/2001

Woodland Hills, CA

Jimerson, Ruthie M .................. 11/27/2000

Youngstown, OH

Jubert, Angela K ....................... 11/27/2000

Anderson, IN

McGinn, Thomas D .................. 01/18/2001

Milford, UT

Mendes, Antonio C ................... 01/18/2001

Canton, MA

Negron, Candido ...................... 01/18/2001

Philadelphia, PA

Omohundro, William A ............. 01/18/2001

S. Pittsburg, Tn

Pinnace, Jeanette L .................. 11/28/2000

Ridley Park, PA

Polee, George .......................... 11/28/2000

Nashville, TN

Rey, Jorge E ............................. 01/18/2001

Chino, CA

Rocha, Mark W ......................... 11/29/2000

Riverside, CA

Smith-Chapin, June D .............. 01/18/2001

Auburn Hills, MI

Soto, Mario J ............................ 01/18/2001

Fresno, CA

Summers, Shawn J .................. 01/18/2001

Los Angeles, CA

Taylor, Berlan L ........................ 01/18/2001

Alicia, AR

Yagow, John T ......................... 01/18/2001

Subject city, state Effective

date

Watertown, WI

Dated: January 8, 2001.

Calvin Anderson, Jr.,

Director, Health Care Administrative

Sanctions, Office of Inspector General.

[FR Doc. 01–1622 Filed 1–19–01; 8:45 am]

BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESS: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Ribonuclease H1—A Protein Expressed

in Escherichia coli From a Cloned

Human RNase H1 cDNA

Robert J. Crouch, Susana Cerritelli,

Sergey Gaidamakov, and Hirofumi

Yamada (NICHD)

DHHS Reference No. E–047–01/0

Licensing Contact: Sally Hu; 301/496–

7056 ext. 265; e-mail: hus@od.nih.gov.

Available for licensing through a

Materials License Agreement (no patent

or patent application) are samples of

purified human RNase H1 protein,

expressed in E. coli from human RNase

H1 cDNA. This protein is important for

cellular functions such as DNA

synthesis and repair. This protein also

is related by sequence, structure and

enzymatic mechanism to the RNase H of

retroviruses such as HIV. Since the

cellular and viral proteins have similar

properties, it would be useful to screen

for potential drugs that have little or

only modest effects on the cellular

protein while inhibiting the HIV

enzyme. Thus, the availability of both

the retroviral and human RNases H1

makes drug screening and anti-sense

therapy possible to perform.

Methods for the Identification of

Textual and Physical Structured Query

Fragments for the Analysis of Textual

and Biopolymer Information

Robert J. Boissy (NIEHS)

DHHS Reference No. E–270–99/0 filed

15 Nov 2000

Licensing Contact: Dale Berkley; 301/

496–7735 ext. 223; e-mail:

berkleyd@od.nih.gov.

The invention comprises algorithms

implemented in software for ‘‘structured

combinatorial queries’’ that may be used

for analyses of relatedness and

information content in any textual

information, and especially in biological

sequences. The invention also includes

experimental methods for isolating and

comparing DNA fragments (‘‘Structured

Query Fragments’’ or SQFs) obtained

using site-specific cleavage effectors

acting on substrate DNA that is

asymmetrically end-immobilized on a

solid support. A small, structured array

of such cleavage effectors may be used

in a combinatorial fashion to generate

progressively expanding sets of

asymmetrically end-immobilized,

double-stranded DNA. This ultimately

yields extremely large numbers of SQFs,

which typically have lengths in the

range of 100–700 nucleotides (and are

termed ranged SQFs). Thus, each SQF is

defined by a method (a specific

combinatorial pathway required to

isolate it) and one or more properties

(typically its length). These attributes

yield sufficient information to identify

and assign ranged SQFs to specific

locations in known sequences

automatically using the software

disclosed in the invention. The

invention shows how millions of

individual ranged SQFs distributed

throughout the human genome may be

unambiguously identified at nucleotide

resolution using a fragment analysis

instrument. Accordingly, the invention

provides a computational method that is

flexible and efficient at comparing large

amounts of textual information

(typically biological sequence data), and

a unique laboratory strategy that

emulates the computational method and

provides a highly scalable approach for

physical analyses of polynucleotides.

This laboratory strategy allows for the

analysis and isolation of large numbers

6638 Federal Register / Vol. 66, No. 14 / Monday, January 22, 2001 / Notices

of specific SQFs of interest, without the

use of cloning techniques or

polynucleotide amplification protocols

that require locus-specific primers.

Probe Using Diffuse-Reflectance

Spectroscopy

Amir H. Gandjbakhche (NICHD), David

W. Hattery (NICHD), James L.

Mulshine (NCI), Paul D. Smith

(ORS), Ernie Hawk (NCI), Victor

Chernomordik (NICHD)

DHHS Reference No. E–309–00/0 filed

06 Oct 2000

Licensing Contact: Dale Berkley; 301/

496–7735 ext. 223; e-mail:

berkleyd@od.nih.gov.

The invention uses an oblique angle

reflectance spectroscopy method to noninvasively quantify the thickness of the

oral epithelium as a means for

quantifying inflammation at sites in the

oral cavity. In this technique, a

toothbrush-sized probe is used to direct

photon sources at two or more oblique

angles and measure the scattered spectra

to determine the thickness of the

epithelial layer. Analysis of the spectra

provides the location of the stroma/

epithelium interface. The invention has

applications in the assessment of drugs

used in the treatment of Leukoplakia,

which is characterized by a thickening

of the oral epithelium as the underlying

stroma remains unchanged. The

invention provides a non-invasive

technique for determining the efficacy

of drugs used to treat the lesion, and

promises to replace the need for

uncomfortable punch biopsies.

Modified HCV Peptide Vaccine

Jay A. Berzofsky (NCI), Pablo Sarobe

(NCI), CD Pendleton (NCI), Stephen

M. Feinstone (FDA)

DHHS Reference Nos. E–192–98/0 filed

21 Aug 1998 and E–192–98/1 filed

17 Aug 1999

Licensing Contact: Carol Salata; 301/

496–7735 ext. 232; e-mail:

salatac@od.nih.gov.

Hepatitis C virus (HCV) is a single

stranded RNA virus responsible for the

majority of non-A non-B hepatitis.

Hepatitis C virus (HCV) has a

worldwide distribution and is a major

cause of liver cirrhosis and

hepatocellular carcinoma in the U.S.,

Europe, and Japan. For this reason,

development of a vaccine against

hepatitis C is of great importance.

The present invention provides

immunogenic peptides of HCV core

protein which elicit an enhanced

immune response, methods for making

these peptides, and methods for using

these peptides for a variety of

therapeutic, diagnostic, and prognostic

applications, including a vaccine. More

specifically, the present invention

provides an isolated peptide, an isolated

HCV core polypeptide, a fragment of an

HCV core polypeptide and nucleic acids

which encode the peptides and

polypeptides of this invention. The

invention provides a modified HCV core

peptide that is more immunogenic than

the corresponding natural core peptide

for eliciting human cytotoxic T

lymphocytes.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–1643 Filed 1–19–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Novel

Technologies for Noninvasive Detection,

Diagnosis, and Treatment of Cancer.

Date: February 23, 2001.

Time: 8 am to 5 pm.

Agenda: To review and evaluate contract

proposals.

Place: National Cancer Institute, 6130

Executive Boulevard, Conference Room J,

Rockville, MD 20852.

Contact Person: Lalita D. Palekar, Scientific

Review Administrator, Special Review,

Referral and Resources Branch, Division of

Extramural Activities, National Cancer

Institute, National Institutes of Health, 6116

Executive Boulevard, Room 8066, Bethesda,

MD 20892–7405, (301) 496–7575.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: January 12, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–1628 Filed 1–19–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Innovative

Cancer Complementary and Alternative

Medicine Initiative in Cancer Centers.

Date: February 19–21, 2001.

Time: 7:00 pm to 6:00 pm.

Agenda: To review and evaluate grant

applications.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Gerald G. Lovinger,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8070, Rockville, MD

20892–7405, 301/496–7987.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: January 12, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–1629 Filed 1–19–01; 8:45 am]

BILLING CODE 4140–01–M